BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets).
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: John M. Kirkwood, Georgina V. Long, Uwe Trefzer, Michael A. Davies, Paolo Antonio Ascierto, Paul B. Chapman, Igor Puzanov, Axel Hauschild, Caroline Robert, Richard Kefford, Vicki L. Goodman, Julie C. Switzky, R. Suzanne Swann, Anne-Marie Martin, Mary E. Guckert, Michael R. W. Streit, Dirk Schadendorf
Institutions: UPMC Hillman Cancer Center, The University of Sydney, Westmead Hospital, Melanoma Institute Australia, Westmead Institute, Charité – Universitätsmedizin Berlin, The University of Texas MD Anderson Cancer Center, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Memorial Sloan Kettering Cancer Center, Vanderbilt University Medical Center, University Hospital Schleswig-Holstein, Institut Gustave Roussy, GlaxoSmithKline (United States), Essen University Hospital
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2269193607